For patients with external genital and perianal warts (EGW)
Rely on...
The two pillars of therapy
Complete and sustained clearance
  • 53.6% of VEREGEN® patients demonstrated complete clearance of EGW vs 35.3% for vehicle1
  • 93.2% of VEREGEN® patients with complete clearance of EGW experienced sustained clearance at 12 weeks posttreatment vs 94.2% for vehicle1
VEREGEN® Complete Clearance Rates vs Vehicle

In two phase 3, randomized, double-blind, vehicle-controlled studies (United States and international) of male and female patients (N=604) aged 18 years and older who had EGW, VEREGEN® or vehicle was applied 3 times daily until complete clinical (visual) clearance of all external genital or perianal warts (baseline and new) or up to 16 weeks. Those patients who experienced complete clearance of all warts were followed for a 12-week treatment-free period to assess sustained clearance.


Consistent, Continuous Dosing for All Patients
VEREGEN copay program is available to all patients

Tolerability and Safety
  • The most common adverse reactions are local skin and application site reactions including (incidence ≥ 20%) erythema, pruritus, burning, pain/discomfort, erosion/ulceration, edema, induration, and rash vesicular1
  • The incidence of patients with local adverse events leading to discontinuation was 2.3%2
  • Severity of erythema, erosion, edema, and induration was maximal at Week 2 of treatment1

VEREGEN® is indicated for the topical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older.

Important Safety Information

VEREGEN® has not been evaluated to treat urethral, intra-vaginal, cervical, rectal, or intra-anal human papilloma viral disease and should not be used to treat these conditions. Avoid use of VEREGEN® on open wounds.

Avoid exposure of VEREGEN®-treated areas to sun/UV-light because VEREGEN® has not been tested under these circumstances. Safety and efficacy of VEREGEN® have not been established in immunosuppressed patients or patients under 18 years of age, or pregnant women, or for the treatment of external genital and perianal warts beyond 16 weeks or for multiple treatment courses.

The most common adverse reactions are local skin and application site reactions including (incidence ≥ 20%) erythema, pruritus, burning, pain/discomfort, erosion/ulceration, edema, induration, and rash vesicular.

VEREGEN® (sinecatechins) Ointment, 15% Full Prescribing Information